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ABSTRACT
Antibiotics are commonly used in dental practice. It has been estimated that 10% of all antibiotic prescriptions are related 
with dental infections. The association amoxicillin-clavulanate was the drug most frequently prescribed by dentists during 
2005, at least in the Valencian Community (Spain). The use of antibiotics in dental practice is characterized by empirical 
prescription based on clinical and bacteriological epidemiological factors, with the use of broad spectrum antibiotics 
for short periods of time, and the application of a very narrow range of antibiotics. The simultaneous prescription of 
nonsteroidal antiinflammatory drugs (NSAIDs) can modify the bioavailability of the antibiotic. In turn, an increased 
number of bacterial strains resistant to conventional antibiotics are found in the oral cavity.
Antibiotics are indicated for the treatment of odontogenic infections, oral non-odontogenic infections, as prophylaxis 
against focal infection, and as prophylaxis against local infection and spread to neighboring tissues and organs.
Pregnancy, kidney failure and liver failure are situations requiring special caution on the part of the clinician when 
indicating antibiotic treatment.
The present study attempts to contribute to rational antibiotic use, with a review of the general characteristics of these drugs.
Key words: Antibiotic, infection, odontogenic, prophylaxis.
RESUMEN
Los antibióticos son fármacos de uso cotidiano en odontología. Se estima que el 10% de las prescripciones antibióticas 
están relacionadas con la infección odontogénica. La asociación amoxicilina-clavulánico fue el fármaco más prescrito 
por dentistas durante 2005, al menos en la Comunidad Autónoma Valenciana. El uso de antibióticos en odontología se 
caracteriza por una prescripción empírica basada en epidemiología clínica y bacteriana, el uso de antibióticos de amplio 
espectro durante periodos breves de tiempo y el manejo de una batería muy reducida de antibióticos. La prescripción 
simultánea de AINES (antiinflamatorios no esteroideos) puede modificar la biodisponibilidad del antibiótico. Se detecta 
un aumento de número de cepas resistentes a los antibióticos convencionales en la cavidad oral.
La indicación antibiótica se realiza para tratamiento de la infección odontogénica, de infecciones orales no odontogénicas, 
como profilaxis de la infección focal y como profilaxis de la infección local y la extensión a tejidos y órganos vecinos.
El embarazo, la insuficiencia renal y la insuficiencia hepática son situaciones que requieren una especial atención del 
clínico antes de indicar un tratamiento antibiótico.
El objetivo del presente trabajo es intentar contribuir a un uso racional de los antibióticos revisando sus características generales.
Palabras clave: Antibiótico, infección, odontogénica, profilaxis.
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INTRODUCTION
Antibiotic treatment is an aspect of pharmacotherapy with 
the particularity of affording both etiological and curative 
action. It was introduced in the mid-twentieth century in the 
form of sulfa drugs (1935), penicillin (1941), tetracyclines 
(1948) and erythromycin (1952). Since then, antibiotics 
have focused much clinical and pharmacological research, 
in response to the progressive challenges posed by bacterial 
infections: identification of new pathogens, the develop-
ment of resistances to antibiotics, the consolidation of new 
diseases, and novel clinical situations (increase in chronic 
processes, survival of patients with disorders considered to 
be fatal until only recently, etc.)  (1).
A good example of the usefulness of these drugs is provided by 
the fact that in the period 1998-2000, the number of daily doses 
of antibiotics per 1000 inhabitants was 30.7 with a cost of 47.18 
euros/1000 inhabitants/day. Furthermore, in Spain during the 
year 2004, the public National Health Care System prescribed 
25.61 million containers of macrolides, combinations of pe-
nicillins, other betalactams and fluorquinolones, with a total 
cost of 336.12 million euros  (2). The fact that no antibiotic is 
included among the 35 most widely consumed generic drug 
products during the year 2004 is misleading. This is because 
antibiotics are generally prescribed for acute episodes and for 
brief periods of time, while the most heavily consumed medici-
nes are those prescribed for chronic processes (antihypertensive 
agents, hypolipidemic drugs, antacids, antiinflammatory drugs, 
bisphosphonates, bronchodilators, etc.).
Bacterial infections are common in dental and oral clinical 
practice; as a result, antibiotic use prescribed for their treat-
ment is also frequent. In Spain, it has been estimated that 
odontogenic infections are the cause of 10% of all antibiotic 
prescriptions (3).
In the Valencian Community (Spain), dentists in the public 
health care system during the year 2005 prescribed a total of 
43,490 antibiotic containers, with a total cost of 274,439.82 
euros. In relative terms, these figures represent 0.94% of the 
total antibiotic containers and 0.51% of the total antibiotic 
expenditure generated by the public health care system in 
the Valencian Community. By pharmaceutical specialties or 
drug products, amoxicillin and the association amoxicillin-
clavulanic acid accounted for 67.8% of all prescriptions and 
59.4% of the global cost. The association amoxicillin-cla-
vulanic acid was the most frequently prescribed treatment, 
representing 38.7% of all prescriptions and 45.7% of the net 
cost. Spiramycin and the association spiramycin and metro-
nidazole in turn accounted for 13.34% of the prescriptions 
and 10.2% of the global expenditure. Lastly, clindamycin 
represented 4% of the prescriptions and 4.2% of the costs. 
In sum, three drug substances and two drug associations or 
combinations of these same three drug substances account 
for 95% of all antibiotic prescriptions made by dentists in 
the context of the public health care system, and 75% of 
the total antibiotic cost.
The present study reviews antibiotic use in dental practice, 
and contributes elements to favor the rational use of such 
medicines.
PARTICULARITIES OF ANTIBIOTIC USE IN 
DENTAL AND ORAL CLINICAL PRACTICE
Dentist use of antibiotics is characterized by a number of 
particularities. In effect, antibiotic prescription is empirical, 
i.e., the clinician does not know what microorganism is res-
ponsible for the infection, since pus or exudate cultures are not 
commonly made. Based on clinical and bacterial epidemiolo-
gical data, the germs responsible for the infectious process are 
suspected, and treatment is decided on a presumptive basis, 
fundamented on probabilistic reasoning (4).
As a result of the above, broad spectrum antibiotics are 
typically prescribed. A broad range of organisms can be iso-
lated from the oral cavity, and although not all of them are 
potential human pathogens, the list of bacteria related with 
oral infections is relatively long (cocci, bacilli, grampositive 
and gramnegative organisms, aerobes and anaerobes).
As has been commented above, a very limited range of drug 
products is typically used – sometimes as few as two or three 
antibiotics. In turn, prescription is characteristically made for 
short periods of time – typically no more than 7-10 days.
The antibiotic sensitivity of the bacteria found within the 
oral cavity is gradually decreasing, and a growing number 
of resistant strains is detected – particularly Porphyromona 
and Prevotella (5), though the phenomenon has also been 
reported for Streptoccocus viridans and for drugs such as 
the macrolides, penicillin and clindamycin  (6,7).
Antibiotic prescription is almost invariably associated with 
the prescription of nonsteroidal antiinflammatory drugs 
(NSAIDs). There are many potential interactions between 
these two drug categories – the most common situation 
being an NSAID-mediated reduction of antibiotic bioavai-
lability and thus effect (8,9), though some combinations of 
drugs such as cephalosporins and ibuprofen, or tetracyclines 
with naproxen or diclofenac, have been shown to exert the 
opposite effect, i.e., an increase in the bioavailability of the 
antibiotic (10,11).
The target: microorganism
The human oral cavity contains a very broad range of 
germs. In effect, some authors speak of  more than 500 
different species, and Liebana even reports that all known 
microorganisms related to the human species are at some 
time isolated from the oral cavity as either transient (the 
majority) or resident species (only a few) (12). Despite this 
great variety of germs, those most commonly isolated from 
oral, dental, apical and periodontal exudates and pus are 
more limited in number – comprising organisms considered 
to be more pathogenic and which focus the majority of 
studies on antibiotic efficacy.
Isla et al. (13) compared the efficacy of antibiotics common-
ly used in dental and oral clinical practice in application 
to the bacteria most frequently isolated in odontogenic 
infections (S. viridans, Peptostreptococcus spp, Prevotella 
intermedia, Porphyromona gingivalis and Fusobacterium 
nucleatum), based on pharmacokinetic and pharmacodyna-
mic (PK/PD) analyses (effect of the human body upon the 
drug, reflected by the plasma concentration profile -phar-
macokinetics-, and the effect of the drug upon the body, as 
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defined by the minimum inhibitory concentration, or MIC 
-pharmacodynamics-. On the basis of the results of their 
study, the authors suggested the recommended clindamycin 
dose to be 300 mg/6 hours, and 500 mg/8 hours or 2000 
mg/12 hours for amoxicillin-clavulanic acid (with 125 mg 
of clavulanate in both cases). In turn, they reported that the 
association spiramycin-metronidazole at the usual dosage 
fails to cover the full bacterial spectrum in infections of this 
kind. The authors concluded that amoxicillin-clavulanic 
acid, clindamycin and moxifloxacin are the antibiotics of 
choice for the treatment of odontogenic infections – though 
they also pointed to the need for clinical trials to confirm 
the usefulness of PK/PD studies in these processes.
Bresco-Salinas et al. (5), in a clinical study of 64 patients with 
acute infection of pulp origin or pericoronaritis, found the 
germs most commonly isolated from the infection zone to 
be Streptoccocus, Enterococcus, Bacteroides, Fusobacterium, 
Porphyromonas, Prevotella and Actinobacillus. In the study 
of sensitivity to different antibiotics, they found amoxicillin 
and the association amoxicillin-clavulanic acid to offer very 
good results in the in vitro control of most of the germs 
identified (resistances < 10%) – though for Bacteroides and 
Prevotella intermedia the bacterial resistance rate was in the 
range of 25%. Antibiotics commonly used in dental practice, 
such as erythromycin, metronidazole or azithromycin, were 
found to be ineffective in application to over 30% of the stra-
ins (39.1%, 50.5% and 33.2%, respectively). Linezolid was 
the antibiotic with the best performance, proving effective 
in 94.6% of the strains. This antibiotic belongs to the family 
of oxazolidinones, which act by inhibiting protein synthesis, 
and which are effective against multiresistant grampositive 
germs and anaerobes. Linezolid is marketed in Spain under 
the brand name of Zyvoxid® (14). The authors consider 
amoxicillin to be the drug of choice in processes of this kind, 
and that clindamycin should be the alternative in the event 
of treatment failure or of patient allergy to penicillin.
Slightly divergent results have been published by Liñares and 
Martin-Herrero (15), who considered amoxicillin-clavulana-
te to be the option with the fewest resistant strains. Amoxi-
cillin shows resistances in 30-80% of all strains of Prevotella 
and Porphyromona, and the macrolides are scantly effective. 
However, in this study, clindamycin and metronidazole were 
seen to be active against all the pathogens examined, except 
Actinobacillus actinomycetemcomitans.
More rotund findings have been reported by Sobottka et 
al. (16), who after isolating 87 pathogens from 37 patients 
with odontogenic abscesses, found 100% to be sensitive 
to amoxicillin-clavulanic acid. Excellent results were also 
obtained with fluorquinolones (moxifloxacin and levofloxa-
cin), with sensitivity in 98% of all strains. The results were 
somewhat more discrete (sensitivity in the range of 70-75%) 
with doxycycline, clindamycin and penicillin.
Kirkwood, in a review on the use of antibiotics in orofacial 
infections (18), considered that although the penicillins 
traditionally have been used for the treatment of odonto-
genic infections, the growing presence of bacteria resistant 
to penicillin have caused other antibacterials – particularly 
clindamycin – to become the drugs of choice for treating infec-
tions of this kind, due to their good tolerance, low emergence 
of resistances, and the high drug concentrations reached in 
bone. In contrast to the above, Swift et al.  (19) indicate that 
despite the recent introduction of many new antimicrobials, 
none have demonstrated significant benefit justifying their re-
placement of penicillin derivatives in application to orofacial 
infections. Furthermore, they consider that the appropriate 
use of these drugs, together with surgery, constitute adequate 
treatment for odontogenic infections.
To summarize, and as pointed out by Morcillo (19), a poly-
microbial flora has been described in odontogenic infections, 
with strict anaerobes, and with a relatively limited microbial 
spectrum (despite the enormous variety of bacteria that 
transit through or colonize the oral cavity). This means 
that of the broad range of antibacterials available, a few 
drugs will suffice to treat odontogenic infections despite 
the empirical approach to management.
Table 1 reports the antibiotics most commonly used in dental 
practice, with an indication of the corresponding doses.
INDICATIONS OF ANTIBIOTIC TREATMENT
The drawback to the evident benefits of antibiotic treatment 
is represented by the undesired effects of their use. On one 
hand there are side effects with repercussions for the patient, 
such as gastric, hematological, neurological, dermatological, 
allergic and other disorders. On the other hand, the develop-
ment of bacterial resistances is of great importance for both 
individual patient and public health – the paradigm in this 
case being the ß-lactamase producing bacterial strains. As 
was demonstrated by Kuriyama et al. (20), ß-lactamase pro-
ducing bacteria are isolated with increased frequency from 
the purulent exudate of odontogenic infections in patients 
that have received previous treatment with beta-lactams, and 
the longer the duration of such prior treatment the greater 
the number of resistant bacterial strains isolated.
Rational antibiotic use is thus required in dental and oral 
clinical practice, to ensure maximum efficacy while at the 
same time minimizing the side effects and the appearance of 
resistances.
Antibiotics are typically prescribed in dental practice for some 
of the following purposes: (a) as treatment for acute odontoge-
nic infections; (b) as treatment for non-odontogenic infections; 
(c) as prophylaxis against focal infection in patients at risk (en-
docarditis and joint prostheses); and (d) as prophylaxis against 
local infection and systemic spread in oral surgery.
TREATMENT OF THE ACUTE ODONTOGENIC 
INFECTION
Despite the high incidence of odontogenic infections, there are 
no uniform criteria regarding the use of antibiotics to treat them. 
Bascones et al. (21), in a consensus document on the subject, sug-
gested that treatment should be provided in some acute situations 
of odontogenic infection of pulp origin as a complement to root 
canal treatment, in ulcerative necrotizing gingivitis, in periapical 
abscesses, in aggressive periodontitis, and in severe infections of 
the fascial layers and deep tissues of the head and neck. 
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They do not recommend antibiotic treatment in chronic 
gingivitis or periodontal abscesses (except in the presence 
of dissemination).
There is considerable agreement that the beta-lactam de-
rivatives are the antibiotics of choice for these processes, 
provided there are no allergies or intolerances. However, 
there is less consensus regarding which drug belonging this 
family should be prescribed. While some authors consider 
the natural and semisynthetic penicillins (amoxicillin) to 
be the options of first choice (22), others prefer the asso-
ciation amoxicillin-clavulanate, due to the growing number 
of bacterial resistance, as well as its broad spectrum, phar-
macokinetic profile, tolerance and dosing characteristics 
(23). As has been commented above, some authors have 
proposed clindamycin as the drug of choice, in view of its 
good absorption, low incidence of bacterial resistances, and 
the high antibiotic concentrations reached in bone (17).
TREATMENT OF NON-ODONTOGENIC INFEC-
TIONS
Non-odontogenic infections include specific infections of the 
oral cavity (tuberculosis, syphilis, leprosy), and nonspecific 
infections of the mucosal membranes, muscles and fascias, 
salivary glands and bone. Bone infections are included here 
on the grounds that many of them may be of dental origin. 
These processes require prolonged treatments, and drug as-
sociations are used that usually include clindamycin, due to 
its capacity to reach high concentrations in bone (24), and 
fluorquinolones (ciprofloxacin, norfloxacin, moxifloxacin) 
– to extend the bacterial spectrum to include gramnegative 
bacilli, grampositive aerobic cocci and, in the case of third 
generation fluorquinolones (moxifloxacin), anaerobes (25). 
An anecdotal observation is that Bystedt et al. (24) found 
the maximum mandibular concentration of antibiotic to 
correspond to doxycycline, with 2.6 µm/gram, versus 0.6 
µm/gram of clindamycin.
It is recommended that empirical treatment with betalacta-
ms associated to fluorquinolones should be limited, since 
both groups of  antibiotics activate common resistance 
mechanisms – thus favoring the appearance of resistances 
in important pathogens such as Pseudomona aeruginosa and 
Acinetobacter spp (26).
The treatment of specific infections caused by mycobacteria 
requires the use of antibiotics for long periods of time (from 
6 months to 2 years), and includes the administration of dap-
sone (a sulfamide analog), clofazimine (a dye with bactericidal 
action) and rifampicin for leprosy, and associations of etham-
butol, isoniazid, rifampicin, pyrazinamide and streptomycin 
for tuberculosis (27). The treatment of syphilis, caused by 
Treponema pallidum, is based on the use of penicillin G ben-
zatine. Administration comprises 2.4 million IU in a single 
intramuscular dose in the primary period, three doses of 2.4 
million IU via the intramuscular route, spaced one week apart, 
in the secondary period. In the tertiary period a first treatment 
is provided with intravenous penicillin G, followed by penicillin 
G benzatine via the intramuscular route once a week during 3 
weeks, involving a dose of 2.4 million IU each.
PROPHYLAXIS OF FOCAL INFECTION
The use of  antibiotics as prophylaxis for focal infection 
is common practice, and has been widely accepted in the 
dental profession. The paradigm of this model of treatment 
is the prevention of bacterial endocarditis, indicated in risk 
patients in the context of any invasive procedure within the 
Drug
substance Administration route Posology Side effects 
Amoxicillin po* 500 mg/8 hours 1000 mg/12 hours 
Diarrhea, nausea, hypersensitivity 
reactions
Amoxicillin-
clavulanic acid po or iv ** 
500-875 mg/8 hours* 
2000 mg/12 hours* 
1000-2000 mg/8 hours** 
Diarrhea, nausea, candidiasis, 
hypersensitivity reactions 
Clindamycin po or iv 300 mg/8 hours* 600 mg/8 hours** Pseudomembranous colitis 
Azithromycin po 500 mg/24 hours 3 consecutive days Gastrointestinal disorders 
Ciprofloxacin po 500 mg/12 hours Gastrointestinal disorders 
Metronidazole po 500-750 mg/8 hours 
Seizures, anesthesia or paresthesia 
of the limbs, incompatible with 
alcohol ingestion 
Gentamycin im*** or iv 240 mg/24 hours Ototoxicity Nephrotoxicity 
Penicillin im or iv 
1.2-2.4 million IU/24 h*** 
Up to 24 million IU/24 
hours**
Hypersensitivity reactions, gastric 
alterations 
Table 1.  Antibiotics commonly used in application to odontogenic infections.
*po:oral route; **iv:intravenous route; *** im:intramuscular route.
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oral cavity – and following the guidelines of the American 
Hearth Association (AHA) (28) (Table 2).
Nevertheless, there are doubts in relation to this practice. 
Firstly, transient bacteremia occurs not only after dental 
treatments such as extractions (35-80%) or periodontal 
surgery (30-88%). It also occurs in the context of tooth brus-
hing (40%) or while chewing gum (20%), and is proportional 
to the trauma caused and to the number of germs coloni-
zing the affected zone. Secondly, not only bacteria cause 
endocarditis, and of those that do cause the disease, many 
are resistant to the antibiotics administered as prophylaxis 
(fundamentally amoxicillin). Lastly, it is known that most 
cases of bacterial endocarditis are not related with invasive 
procedures, and that dental care is only responsible for a 
minimum percentage of cases of the disease.
Despite the mentioned inconveniences, antibiotic pro-
phylaxis is still recommended in patients at risk (29). Howe-
ver, the results of a survey conducted by Tomas-Carmona et 
al. (30) on the knowledge and approach to the prevention of 
bacterial endocarditis among Spanish dentists showed that 
fewer than 30% of the professionals were aware of correct 
antibiotic indications and posology.
There is no scientific basis for recommending systematic 
antibiotic prophylaxis prior to invasive dental treatment in 
patients with total joint prostheses (31). Jacobson published 
a study on 2693 patients with total joint replacement (hip or 
knee). In 30 of the patients he detected infection of the pros-
thesis, and in only one case was a time relationship with prior 
dental treatment established. Furthermore, 54% of the germs 
isolated were Staphylococcus aureus and epidermidis (32).
According to the American Dental Association and the 
American Academy of Orthopedic Surgeons, evaluation 
is required of antibiotic prophylaxis in patients with total 
joint prostheses in the presence of immune deficiency, when 
contemplating high risk dental procedures in patients with 
prostheses in place for less than two years, and in patients who 
have already suffered past joint prosthesis infections (33).
PROPHYLAXIS OF LOCAL INFECTION AND 
SYSTEMIC SPREAD
Prophylaxis of local infection is taken to comprise the ad-
ministration of antibiotics on a pre-, intra- or postoperative 
basis, to prevent bacterial proliferation and dissemination 
within and from the surgical wound. Few clinical studies to 
date have evaluated this type of treatment. Some authors have 
reported its efficacy, with statistically significant differences in 
the frequency of infectious complications in surgical extrac-
tions of lower third molars between patients who had received 
some form of antibiotic treatment and those without (34).
In a retrospective study of infections following periodontal surgery 
in 390 patients and involving 1053 surgical procedures carried out 
by Powell et al. (35), the reported total frequency of infections was 
found to be 2.09% - no differences being recorded between those 
patients administered antibiotics perioperatively and those without. 
The authors therefore did not consider it to be justified to administer 
antibiotics on a postoperative basis with the sole purpose of avoiding 
postoperative infections in operations of this type, which included 
curettage with flap raising, the placement of implants, sinus lifting, 
soft tissue autografts and coronal displacement flaps.
In a consensus document on the use of  antibiotic pro-
phylaxis in dental surgery and procedures published in 2006 
(36), prophylaxis in oral surgery in a healthy patient was 
only recommended in the case of the removal of impacted 
teeth, periapical surgery, bone surgery, implant surgery, bone 
grafting and surgery for benign tumors. In subjects with risk 
factors for local or systemic infection - including oncologi-
cal patients, immune suppressed individuals, patients with 
metabolic disorders such as diabetes, and splenectomized 
patients, prophylactic antibiotic coverage should be provided 
before attempting any invasive procedure.
The use of antibiotics in endodontics should be reserved 
for patients with signs of local infection, malaise of fever. 
Prophylactic or preventive use should be reserved for en-
docarditis and the systemic disorders commented above 
– avoiding indiscriminate antibiotic use (37).
Antibiotic Indication Dose Timing 
Amoxicillin Standard 2 g po, *50 mg/kg po 1 hour before 
Ampicillin If oral route cannot be used
2 g im or iv, *50 mg im or iv ½ hour before 
Clindamycin 
Allergy to penicillin 
Allergy to penicillin and 
oral route cannot be used 
600 mg po, *20 mg/kg 
600 mg po or iv, *20 mg/kg iv 
1 hour before 
½ hour before 
Cephalexin or 
cefadroxil Allergy to penicillin 




Allergy to penicillin 500 mg po, *15 mg/kg po 1 hour before 
Cefazolin Allergy to penicillin and oral route cannot be used 
1g im or iv, *25 mg/kg ½ hour before 
Table 2. Antibiotic prophylaxis against bacterial endocarditis in oral procedures (AHA).
*pediatric dose; *po:oral route; **iv:intravenous route; *** im:intramuscular route.
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PRECAUTIONS WITH ANTIBIOTIC USE
- Pregnancy
The legal and ethical impossibility of conducting clinical 
trials in humans to evaluate the risks of antibiotic treatment 
during pregnancy has given rise to uncertainties as to the use 
of such drugs in these patients. The United States Food and 
Drug Administration (FDA) has established four levels of 
drug risk during pregnancy: (A) without demonstrated risk; 
(B) without effects in animals, though with undemonstrated 
innocuousness in humans; (C) no studies conducted in either 
animals or humans, or teratogenic effects recorded in ani-
mals without due evaluation in humans; and (D) teratogenic 
effects upon the fetus – use of the drug being conditioned 
to the obtainment of benefit that outweighs the risks. A 
final group (X) in turn contemplates teratogenic effects that 
outweigh any possible benefit derived from the drug.
No antibiotic corresponds to group A. On the other hand, 
group B (i.e., warranting caution with treatment during 
pregnancy) contains the following antibiotics: azithromycin, 
cephalosporins, erythromycin, metronidazole and penicillins 
with or without beta-lactamase inhibitors. Group C in turn 
includes clarithromycin, the fluorquinolones and the sulfa 
drugs (including dapsone). Finally, group D contains the 
aminoglycosides and tetracyclines (38).
- Kidney failure
Many antibiotics are actively eliminated through the ki-
dneys. The presence of impaired renal function requires 
reduction of the drug dose in order to avoid excessively 
elevated plasma drug concentrations that could lead to 
toxicity. dose adjustment can be carried out by reducing the 
amount administered in each dose or by increasing the inter-
val between doses (without modifying the amount of drug). 
Neither approach has been shown to be superior (39).
Table 3 reports some of  the antibiotics most frequently 
used in dental practice, with the dose adjustments required 
according to the degree of kidney failure (assessed according 
to creatinine clearance).
- Liver failure
Some antibiotics are metabolized in the liver, followed by 
elimination in bile. In patients with liver failure, the use 
of such antibiotics should be restricted in order to avoid 
toxicity secondary to overdose. Erythromycin, clindamycin, 
metronidazole and anti-tuberculosis drugs are antibiotics 
requiring dose adjustments when administered to patients 
with liver failure.
Regardless of the above considerations, some antibiotics are 
potentially hepatotoxic. As a result, and whenever possible, 
they should be avoided in patients with some active liver 
disorder. Specifically, tetracyclines and anti-tuberculosis 
drugs should be avoided (40).
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